Results 121 to 130 of about 2,517,757 (289)

Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane   +19 more
wiley   +1 more source

Letter to the Editor

open access: yesSwiss Medical Weekly, 2011
CT Chao
doaj   +1 more source

Core-CT extra. 2001: Nov. 13.

open access: yes, 2001
Began with Oct. 2, 2001; ceased with No. 38 (Sept. 22, 2004).; Numbering begins with No. 2 (Oct.

core  

Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker‐Defined Synucleinopathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Isolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal state for Lewy body disorders and exhibits biological heterogeneity that may influence clinical expression and progression. We examined clinical features in individuals with iRBD and biomarker‐defined synucleinopathy.
Daniel Weintraub   +24 more
wiley   +1 more source

Core-CT extra. 2003: Dec. 15.

open access: yes, 2003
Began with Oct. 2, 2001; ceased with No. 38 (Sept. 22, 2004).; Numbering begins with No. 2 (Oct.

core  

Comprehensive Assessment of Arterial, Tissue, and Venous Collaterals for Evaluating the Infarct Growth Rate: The Multimodal Collateral Score

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Collaterals are crucial factors that influence the infarct growth rate (IGR). We aimed to determine whether a comprehensive multimodal collateral score (MCS), incorporating collateral assessment at the arterial, tissue, and venous levels, is associated with functional independence and provides incremental prognostic value over ...
Giorgio Busto   +12 more
wiley   +1 more source

Core-CT extra. 2004: Jan. 22.

open access: yes, 2004
Began with Oct. 2, 2001; ceased with No. 38 (Sept. 22, 2004).; Numbering begins with No. 2 (Oct.

core  

Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro   +6 more
wiley   +1 more source

Study on Predicting Clinical Stage of Patients with Bronchial Asthma Based on CT Radiomics

open access: yesJournal of Asthma and Allergy
Xiaodong Chen,1,* Xiangyuan Wang,1,* Shangqing Huang,1 Wenxuan Luo,1 Zebin Luo,1,* Zipan Chen2,* 1Radiology Imaging Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang City, People’s Republic of China; 2Health ...
Chen X   +5 more
doaj  

Core-CT extra. 2002: Oct. 25.

open access: yes, 2002
Began with Oct. 2, 2001; ceased with No. 38 (Sept. 22, 2004).; Numbering begins with No. 2 (Oct.

core  

Home - About - Disclaimer - Privacy